NAS8
NOTICE OF ACCEPTANCE OF SEC. 8 - E-MAILED
10/31/2022
Back to search
Official data from USPTO
QUANTISCRIPT
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: CombinedOffice: US
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
29
Latest update
11/25/2022
Classification
Registered
Trademark type
Combined
Nice classes
1, 5
Filing date
05/30/2000
Registration date
05/28/2002
Expiration date
-
Recommended action
Perform a full collision analysis and validate classes before any filing or trademark investment.
Next step
These are the details of the registration process. Even so, constant monitoring is what ensures peace of mind that your main asset remains protected.
Complete case details
Structured fields from the responsible authority and the official record.
Status date
10/31/2022
Last transaction
11/25/2022
Responsible office
United States Patent and Trademark Office
Status code
800
Official register
Principal Register
Filing basis
Intent to use, Foreign priority
Drawing code
5
Owner type
03
Owner location
Hilden, DE
Examiner
LEVINE, HOWARD
Law office
M60
Current location
TMO LAW OFFICE 115
Holders and representatives
Holders
Qiagen GmbH
Qiagen GmbH
Representatives
Victoria Friedman Dennemeyer & Associates, LLC
Technical classification
Nice Classes
Class 1Class 5
Vienna Codes
No Vienna codes available.
Goods and services
Class 1
Chemicals for use in the manufacture of nucleic acids; reagents for diagnostic purposes for scientific and research use; enzymes used for scientific and research use and for use in the preparation of nucleic acidsin the process of RNA and DNA synthesispolymerase chain reactionreverse transcriptase polymerase chain reaction and primer-extension analysis
Class 5
reagents for clinical or medical laboratory use; enzymes used for clinical or medical laboratory use; enzymes for medical treatment purposes used in the preparation of nucleic acids
Publications
History of USPTO decisions and trademark events.
29 publications found
RNL2
REGISTERED AND RENEWED (SECOND RENEWAL - 10 YRS)
10/31/2022
9G8P
REGISTERED - SEC. 9 GRANTED/CHECK RECORD FOR SEC. 8
10/31/2022
8PRT
REGISTERED - PARTIAL SEC. 8 (10-YR) ACCEPTED
10/31/2022
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
10/31/2022
E89R
TEAS SECTION 8 & 9 RECEIVED
04/29/2022
REM2
COURTESY REMINDER - SEC. 8 (10-YR)/SEC. 9 E-MAILED
05/28/2021
NA89
NOTICE OF ACCEPTANCE OF SEC. 8 & 9 - E-MAILED
06/07/2012
RNL1
REGISTERED AND RENEWED (FIRST RENEWAL - 10 YRS)
06/07/2012
89AG
REGISTERED - SEC. 8 (10-YR) ACCEPTED/SEC. 9 GRANTED
06/07/2012
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
06/07/2012
E89R
TEAS SECTION 8 & 9 RECEIVED
05/25/2012
C15A
REGISTERED - SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK.
03/24/2008
PLGL
ASSIGNED TO PARALEGAL
03/11/2008
E815
TEAS SECTION 8 & 15 RECEIVED
03/05/2008
CFIT
CASE FILE IN TICRS
09/11/2007
CORV
REVIEW OF CORRESPONDENCE COMPLETE
09/09/2006
PAPER RECEIVED
08/21/2006
R.PR
REGISTERED-PRINCIPAL REGISTER
05/28/2002
PUBO
PUBLISHED FOR OPPOSITION
03/05/2002
NPUB
NOTICE OF PUBLICATION
02/13/2002
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
09/19/2001
DOCK
ASSIGNED TO EXAMINER
09/19/2001
DOCK
ASSIGNED TO EXAMINER
09/15/2001
44DD
SEC. 44(D) CLAIM DELETED
04/27/2001
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
04/27/2001
CNRT
NON-FINAL ACTION MAILED
11/01/2000
DOCK
ASSIGNED TO EXAMINER
10/27/2000
DOCK
ASSIGNED TO EXAMINER
10/25/2000
Continuous trademark protection
Get notified about every new filing that threatens QUANTISCRIPT or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.